Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
复制标题
Gelstat 偏头痛（舌下含服小白菊和生姜化合物），用于在轻度疼痛阶段急性治疗偏头痛。
DOI：
--
复制
发表时间：
2005
影响因子：
3.1
通讯作者：
Carolyn C. Hart
中科院分区：
文献类型：
--
作者：
R. Cady;Curtis P. Schreiber;M. Beach;Carolyn C. Hart
背景
偏头痛的治疗往往被推迟，由于评估一个不断发展的头痛的潜在严重程度或预期从处方药不必要的后果。研究表明，当在偏头痛的轻度头痛阶段进行处方治疗时，无痛反应得到改善。本研究旨在评估OTC产品GelStat Migraine在偏头痛早期轻度疼痛阶段的疗效。
材料/方法
一项开放标签研究，招募了30名男性和女性受试者，他们有一年的偏头痛病史，符合IHS诊断标准，有或没有先兆，每月偏头痛2-8次，每月头痛天数≤ 15天。入选标准要求患者在至少75%的偏头痛发作中，持续从轻度开始，如果未经治疗，则恶化为中度或重度。受试者还必须能够区分偏头痛和非偏头痛，并在发作过程中早期可靠地识别偏头痛。一个头痛是在轻度疼痛阶段用GelStat偏头痛治疗的，这是一种小白菊和生姜的组合。
结果
29例可评价受试者完成了研究，所有受试者均接受轻度疼痛治疗。治疗后两小时，48%的患者没有疼痛，34%的患者报告头痛程度仅为轻度。29%的患者在24小时内复发。副作用很小，不严重。59%的受试者对Gelstat偏头痛治疗感到满意，41%的受试者首选Gelstat偏头痛或认为其与研究前药物相当。
结论
GelStat Migraine在轻度头痛阶段早期开始时作为偏头痛的一线流产治疗是有效的。
BACKGROUND
Treatment of migraine headaches is often delayed due to assessing the potential severity of an evolving headache or anticipating unwanted consequences from prescription medication. Studies have demonstrated improved pain-free response when prescription treatments are taken during the mild headache phase of a migraine. This study was designed to evaluate the efficacy of an OTC product, GelStat Migraine, when taken in the early, mild pain phase of migraine.
MATERIAL/METHODS
An open-label study enrolling 30 subjects, male and female, with a one-year history of migraine meeting IHS diagnostic criteria with or without aura, 2-8 migraines per month and < or = 15 headache days per month. Inclusion required having migraines that consistently started at mild and worsened to moderate or severe, if untreated, in at least 75% of attacks. Subjects also had to be able to distinguish migraine from non-migraine headaches and reliably identify migraine early in the course of an attack. One headache was treated in the mild pain phase with GelStat Migraine, a combination of feverfew and ginger.
RESULTS
29 evaluable subjects completed the study, all treating at mild pain. Two hours after treatment, 48% were pain-free with 34% reporting a headache of only mild severity. 29% reported a recurrence within 24 hours. Side effects were minimal and not serious. 59% of subjects were satisfied with Gelstat Migraine therapy and 41% preferred GelStat Migraine or felt it was equal to their pre-study medication.
CONCLUSIONS
GelStat Migraine is effective as a first line abortive treatment for migraine when initiated early during the mild headache phase.